SCM
SPRB

Squadron Capital Management’s Spruce Biosciences SPRB Stock Holding History

Squadron Capital Management’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,200
Closed -$797K – 60
2026
Q1 		$797K Sell
12,200
-57,800
-83% -$3.99M 0.29% 35
2025
Q4 		$6.1M Buy
+70,000
New +$7.5M 2.58% 14

Other funds holding SPRB

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

Squadron Capital Management's SPRB Position: Q2 2026 in Review

Squadron Capital Management sold out of Spruce Biosciences (SPRB) in Q2 2026, closing a stake of 12,200 shares — an estimated $797K sold.

Squadron Capital Management first reported a position in SPRB in Q4 2025 and held it in 2 quarters. The position peaked at $6.1M in Q4 2025. 63 funds tracked by Wall St. Rank hold SPRB as of Q2 2026.

  • Squadron Capital Management reported no remaining Spruce Biosciences position as of Q2 2026 after selling out during the quarter.
  • Squadron Capital Management sold 12,200 Spruce Biosciences shares in Q2 2026, an estimated $797K.
  • Squadron Capital Management first reported a position in Spruce Biosciences in Q4 2025 and held it in 2 quarters.
  • Squadron Capital Management's Spruce Biosciences position peaked at $6.1M in Q4 2025.
  • 63 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2026.

Based on Squadron Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.